Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses
This article was originally published in The Pink Sheet Daily
The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.
You may also be interested in...
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Having emerged from a radical restructuring with new senior management, a revamped portfolio and a strategic ambition to morph into an oncology powerhouse on the back of its emerging markets business, CEO Belén Garijo says Merck Serono is poised to enter its growth phase.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.